Clearstead Trust LLC reduced its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 24.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,312 shares of the company’s stock after selling 2,032 shares during the quarter. Clearstead Trust LLC’s holdings in ARK Genomic Revolution ETF were worth $149,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of ARKG. Hemington Wealth Management increased its stake in shares of ARK Genomic Revolution ETF by 44.6% in the fourth quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock valued at $30,000 after buying an additional 404 shares in the last quarter. Wealthcare Advisory Partners LLC increased its stake in shares of ARK Genomic Revolution ETF by 2.8% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 15,903 shares of the company’s stock valued at $374,000 after buying an additional 435 shares in the last quarter. Avantax Advisory Services Inc. increased its stake in shares of ARK Genomic Revolution ETF by 2.5% in the fourth quarter. Avantax Advisory Services Inc. now owns 28,701 shares of the company’s stock valued at $676,000 after buying an additional 702 shares in the last quarter. National Bank of Canada FI increased its stake in shares of ARK Genomic Revolution ETF by 28.4% in the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after buying an additional 920 shares in the last quarter. Finally, Ping Capital Management Inc. increased its stake in shares of ARK Genomic Revolution ETF by 7.1% in the fourth quarter. Ping Capital Management Inc. now owns 15,000 shares of the company’s stock valued at $353,000 after buying an additional 1,000 shares in the last quarter.
ARK Genomic Revolution ETF Trading Down 3.6 %
ARK Genomic Revolution ETF stock opened at $22.76 on Friday. The business’s 50-day simple moving average is $25.75 and its 200 day simple moving average is $25.18. ARK Genomic Revolution ETF has a 12-month low of $21.56 and a 12-month high of $31.16.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Read More
- Five stocks we like better than ARK Genomic Revolution ETF
- How to Start Investing in Real Estate
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Read Stock Charts for Beginners
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is a Low P/E Ratio and What Does it Tell Investors?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.